Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025
Thursday, July 24, 2025 1 min read
Key Takeaway: Kiniksa Pharmaceuticals International, plc will hold a conference call on July 29, 2025, to discuss its second quarter financial results and recent portfolio developments. The call will be accessible via a live webcast and telephone registration. A replay will be available shortly after the event.
Price reaction · baseline $26.9 (2025-07-24 close) · hit after-hours · 1 other KNSA headline(s) in the window, move may be shared
day 0 close · peak
-2.1%
Market Sentiment Analysis
POSITIVE FACTORS
Kiniksa Pharmaceuticals will report financial results, indicating business activity.
The company is focused on developing therapies for unmet medical needs.
The event includes a live webcast, enhancing accessibility for investors.
Full Press Release Details
LONDON, July 24, 2025 (GLOBE NEWSWIRE) --Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website atwww.kiniksa.com. Individuals interested in participating in the call via telephone may registerhere. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visitwww.kiniksa.com.